1217601-58-5
Chemical Structure
Pramipexole-d5 dihydrochloride
- CAS No.: 1217601-58-5
- Formula:C10H14D5Cl2N3S
- Molecular Weight:289.28
IUPAC Name: (S)-N6-(propyl-2,2,3,3,3-d5)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride
InChIKey: QMNWXHSYPXQFSK-DTYNNZMFSA-N
SMILES: NC1=NC2=C(S1)C[C@H](CC2)NCC([2H])([2H])C([2H])([2H])[2H].Cl.Cl
Biological Activity: Pramipexole-d5 dihydrochloride is deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pramipexole-d5 dihydrochloride | 97.72% | Pramipexole-d5 dihydrochloride is deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pramipexole dihydrochloride (Standard) | ≥98% | Pramipexole (dihydrochloride) (Standard) is the analytical standard of Pramipexole (dihydrochloride). This product is intended for research and analytical applications. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pramipexole-d7 dihydrochloride | Pramipexole-d7 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pramipexole-d7-1 dihydrochloride | Pramipexole-d7-1 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pramipexole dihydrochloride | 99.85% | Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [Content Brief]
- [3]. Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71. [Content Brief]
